• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Diatide's AcuTect gets priority review

Article

Peptide-based radiopharmaceutical developer Diatide reported last week that the Food and Drug Administration has accepted the company's new drug application (NDA) filing for AcuTect, and has placed the NDA under priority review status. The FDA reserves

Peptide-based radiopharmaceutical developer Diatide reported last week that the Food and Drug Administration has accepted the company's new drug application (NDA) filing for AcuTect, and has placed the NDA under priority review status. The FDA reserves priority review for products that could be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious or life-threatening disease, according to Londonderry, NH-based Diatide. Receipt of the status means that the review time for AcuTect will most likely be cut in half, with the FDA completing its review in six months. AcuTect is designed for the detection of acute venous thrombosis (SCAN 9/3/97).

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.